Pharma Deals Review, Vol 2004, No 50 (2004)

Font Size:  Small  Medium  Large

Alnylam and Merck Sign Second RNAi Agreement in 10 Months

Business Review Editor

Abstract


Alnylam entered into a deal with Merck & Co. to develop and commercialize RNAi therapeutics for ocular diseases particularly age related macular degeneration. The deal is worth up to US$19.5 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.